3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
127
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Burkitt Lymphoma
26
Myelodysplastic Syndromes
25
Leukemia
25
Leukemia, Biphenotypic, Acute
21
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Mantle-Cell
14
Recurrence
13
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Myeloproliferative Disorders
9
Lymphoma
9
Lymphoma, Non-Hodgkin
8
Leukemia, Myelomonocytic, Chronic
8
Lymphoma, Large B-Cell, Diffuse
7
Down Syndrome
6
Neoplasm, Residual
5
Hodgkin Disease
5
Blast Crisis
5
Sarcoma, Myeloid
4
Lymphoma, T-Cell
4
Leukemia, Monocytic, Acute
4
Hematologic Neoplasms
4
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Neoplasms
2
Multiple Myeloma
2
Lymphoma, B-Cell
2
Interventions
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Biopsy
6
Nuclear Medicine Department, Hospital
5
Etoposide
5
Nivolumab
4
Bevacizumab
4
Radiation
3
Irinotecan
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
abemaciclib
2
Watchful Waiting
2
Radiotherapy
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Cytarabine
×
1 year
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled